Close Menu

NEW YORK – With the scuttled Thermo Fisher Scientific acquisition in its rearview mirror, Qiagen is ready to continue life as an independent company, with recently acquired in vitro diagnostics developer NeuMoDx serving as a key pillar of future growth.

While Qiagen's diverse portfolio of sample technologies and molecular testing products has enabled it to maintain short-term growth during the COVID-19 pandemic, the company believes it has the pieces in place for growth beyond SARS-CoV-2 testing tailwinds, CEO Thierry Bernard said in a recent interview.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

Sponsored by
Thermo Fisher Scientific

Global genetic surveillance is vital for understanding the evolution of viral pathogens and monitoring for changes in transmissibility, virulence, disease pathology, and impact on the efficacy of diagnostic tests, therapeutics, and vaccines.

Sponsored by

This webinar will outline the development and commercialization journey of a novel CRISPR-based SARS-CoV-2 test.